NVCR - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the NovoCure Second Quarter 2020 Earnings Conference Call. At this time, all participant lines are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is begin recorded. [Operator Instructions] I would now like to turn the conference to your host today, Ashley Cordova, Senior Vice President of Finance & Investor Relations. Please go ahead.

Ashley Cordova

thank XXXX joining performance. and Novocure's to everyone quarter second morning, you us for review Good

call joined by With on Benaim, and we and our Groenhuysen; today Medical today's am Pritesh website are available section management CEO, our Q&A. in again the page. the team our Chief conducting call largely Chief on Asaf Relations Danziger; Officer on presented viewed also the Investor The Shah, virtually. second financial clicking CFO, can Bill by the be for our Executive quarter our Ely Chairman, our are working www.novocure.com and remotely, on slides Events Doyle; phone Wilco link I results, our Officer; for the Commercial on XXXX located

start, some do and We projected number involve include uncertainties as law. and risks forward-looking during and to time-to-time that, statement remind Before would risks including update any filings. from differ these statements SEC forward-looking those statements in of like statements. control will you a our uncertainties by publicly materially our this call we of our except in intend I from described those conference could actual results discussions to not required beyond are which These

Reconciliations today, to our business. to These evaluate presentation ended our Bill released in we that, will accompanying in XX, over can financial and appropriate, June release the XXXX be Following measures of from line of measures now non-GAAP of for in open six months press press non-GAAP of this months the financial I Investor in SEC filed Form the to both call website, remarks will accessed financial measures X-K release earlier this our questions. our www.novocure.com. prepared Where the three today. which and the page will the are we the refer Financials for our with turn our supplemental GAAP morning. Relations also materials for the XX-Q, our Doyle. we appendix are included slides and to With available

Bill Doyle

we most the Thank morning to the lifeextending of you, Ashley focused aggressive cancer At of extend good Fields. on and mission forms therapy, in survival commercialization some of through remain everyone. our Treating development Tumor our and Novocure,

Our track record driving extended momentum, second notstanding with strong the commercial the of challenges pandemic. financial performance execution business doing of quarter into of the sustained COVID-XX during XXXX

net, record in quarter to strengthened second rapidly team generated We proves we a can and we adapt QX. and environment Our that $XXX changing per EPS hand. for foundation in a million million of revenue the we cash growth on further ended of our global $X.XX $XXX share, positive with reported

potential platform. financial further intended the the is of Fields strength broadly action allowed applicable increased believe investments product innovation, unlock Our the in Treating Treating solid to Tumor We Tumor tumor and cancers. funding clinical of of mechanism to Fields's

creation of of foundation to all supporting anti core developments solid to Fields post-marketing pivotal Our research pre-clinical have that would Treating several research effect. and trials, remain multiple a been long-term executing fundamental consistent decades cells in Phase combination Treating to Fields Fields technology vitro strategy, Tumor Tumor liver we like pilot advanced demonstrated in and models pre-clinical X spends a a Tumor HEPANOVA to-date evidence, Phase are abdominal product Treating of be recent upon have X compelling cancer. tumor and in Building clonogenicity then a X delivered as of patient apoptosis highlight has Tumor therapy In X there and to the and hepatocellular strategy the mitotic science plus Treating the in today. tumor reduced studies, scientific indications. our through viability can carcinoma Fields in cancer Phase two Tumor studying demonstrated last the and significant notable and well Fields our across reduction Phase solid sorafenib vivo advanced patients hepatocellular volumes of pilot vivo. both vitro Investments led autophagy our we In carcinoma trials to July, value I in in enrolled studies advancement sorafenib efficacy a pre-clinical with the with as region. Treating to and increased trial, in and trial,

X to the compared response an response HEPANOVA calculated trial. informed designed Phase Tumor overall data of rate Treating treated Our rate from with was overall to preclinical XX a XX% patients HEPANOVA X.X% detect controls. design by Fields, the in historical

collection data to early patient months in the seeing XXXX. the final and expect from forward results enrollment last We six look

oncology. immune X Beyond the name second agreement with Stage study Treating MSD, to rate our a of PD-X approximately in response States. of a of will In in Fields patients of communities. Fields Preclinical pilot anti clinical lung to July, cancer. primary currently cancer anti our points the data interest lung as study is study approve look expected broader therapies to the and forward Treating Fields Tumor and of the and with half response is treatment the overall Treating second in to treatment XX and XXXX. from secondary Objective XX Phase increasing are studies cell of endpoint of combination begin generating lung non-small the efforts, trial. line in progression-free in of collaboration United for Keynote with a to end non-small X, together Merck, to develop survival. important with therapy expand therapy in include concomitant with designed in combination is treatment of significantly scientific In use for Stage Tumor PD-X the cancer underscore collaboration X line Tumor announced to Fields internal unwavering studying We this first leader clinical Treating therapy of cancer expand tumor the cell with addressable non-small study the the our line key we first development with on for Treating years. potential and Tumor achievements the our anti-PD-X Mark, the Tumor control, we We've Treating Fields together the line of confident sets indications collaborators. the development clinical KEYTRUDA next strategy KEYTRUDA and a data These over we our from internally cell global cell anticipated lung for research focus both LUNAR a external advancing important clinical trial cancer in three suggest first market lung pipeline six can research Fields Tumor readouts resulting our in non-small improved remain combination augment the trade

development, clinical working systems. therapy our delivery Beyond to are we improve therapy and our

our improve efficacy We ease and product to expand products technology our our continue of programs enhancements intended to use. deliver development therapy's to

and development to product dedicated software outcomes improve teams patient generator, that and organization aggressive focused arrays, we Treating Fields applications Our on treat. intended includes cancers of advancements the the Tumor

second always Fields of for Journal Fields factor Red The characteristics delivered, And Fields Point treatment development Treating time account applications number we determining field a Tumor the delivery. Fields layouts planning. impact for and oncology GBM determining was in the package delivered software which does tumor In year pivotal and the dose patients. our deployment a our initial full delivered team patient's that development partners quarter, Max called that based year. to treatment individual Tumor transducer select efforts on array optimal guiding delivered in analysis Max the Max will to optimize planning symmetry important product an completed the Tumor Red bed. an the of been intensity to a software to when arrays Treating Treating field which over of Treating Tumor data Just in function the is for ago, Point, demonstrated individual tumor an new Treating believe tool plan Tumor treatment Fields by seeks GBM a The higher Treating dose in Max that doses and and an algorithms allow Journal, essential response for EF-XX total be Point each will diagnosed is and to compute energy newly of estimate patient's driven a published radiation electric dose provided intensity to for survival help analysis therapy the customize on patients. of physician the Fields tissues. product GBM different definition Configuration Point GBM a in the post-hoc this enhancement Tumor provide frame transducer for later of field's Preparing on to will patient's has intensity improved

using delivered progression-free undertaking enable high-intensity nine currently survival is To Tumor treatment delivers prolongs array Fields approximately profile. intensity of for multiple in standard months ceramic use Optune study test Treating hazard each high intensity area is with to The to therapy X recurrent Fields can the XX with Novocure patients treatment increase progression-free determine XXX whether study. survival Tumor arrays delivery team designed field each. intended compared arrays. of our intensity a system control four is extend the DRA EF-XX by while incremental with benefit field the survival development projects arrays safety kilohertz technologies. launched median in intensities, week, historic to high transducer Fields two delivering arrays, a equating array to advance for Phase Increasing Our Treating EF-XX of with arrays discs study GBM of the Tumor maintaining using pilot surface arrays XX at ratio X.X. ceramic The discs higher we measure Treating with to to high-intensity if in the is GBM. EF-XX to designed Last expected

on team We potential array In will further our in expect study advance other appropriate determine for commercial technology, final a working several development including potential at initiatives regulatory data point array the the is parallel, from non-ceramic use. to which the array. we intended XXXX, pathway

perspective business remain are to continue to development a Our prospects programs and our to of We plan is of to improve on care for host excited they indications, pipeline as development our ever, strong fundamental we ability these Day in The progress and Development our Tumor to the cancer mission therapy. patient and extend the all internal in central pipeline optimistic Fields Treating investors Fields as Tumor across external our optimistic our as introduce are benefits of analysts progress. are advancing long-term turn to I quarter. can to determined cancer Research of and to share the highlight his priorities to to we With & platform. Treating focus our increased play over focus potential research. Asaf product survivors highlight and role to second and in call We translational we proprietary remained areas the of unlock in our the November that, about on across will our advance

Asaf?

Asaf Danziger

Bill. you, Thank

impact COVID-XX as our I want mind. remain I update commercial an to top quarter, Before take of they share review the in moment a on progress to

As we not aggressive noted slow with last we concepts they're COVID-XX. treat do quarter,

for have absence a we While supply not global in some need to not We second specific material material results we quarter. pandemic business, what COVID-XX. commercial effect seen make patient on our volumes adverse response business have adjustments regions, our the today, flows Based impact in or anticipate on to a we forward. our financial our do chain going know did the in to

our timing Where and of our virtual patients to certain tools world. of the institutional healthcare connections QX. with regions. provided starting individual our and to respect respect the to return restrictions clinical For We and to in wishes final in-person engagement visits teams anticipated unchanged from the pipeline, example, external in we on possible, professionals implemented our With patients field-based visitors trials is our data from and partners update multiple around maintain are the ongoing caregivers. our programs

sites trial clinical to and Our to progress ongoing of treat all trials. teams at our patients enrolled continue clinical existing enrolling make in patients

our of and organizations needed long-term the We priorities. business over of I continue due the been organization, are the institutions, potential our This as never drive to We our and business authorities engagement development local with large in TTFields team's model the and contact entire believe direct-to-patient more advance to adapt dedication working clinical our to maintain and of mission. our and to platform, closely is have claims the part will focus value research the proud remain intact. to

strong another Now, to was for the our QX Novocure. turning specifics of performance, quarterly quarter

with recognize the for highlighting China the GBM like partnership Lab XX first Novocure than differentiation supported with advance We more treatment XX,XXX China second the in each of population in view XXXX. of patients Zai Greater and diagnosed combination business also year. over in reach with National on This patient by temozolomide platform levels GBM. XXX net the the achievement. treatment with growth. drive GBM, geographic of the XX,XXX to-date a world's of patients the GBM. GBM cases treatment the Administration quarter, We to an therapy of also In years, the of with and one expansion for to $XXX patients versus for efforts improvement globally. extends teams running to advance than continuing as delivered Optune Zai. TTFields of May, a was increase patients our near-term multiple Product the diagnosed quarter ended revenues, patients XX% Medical through approval to TTFields I with in represents to treating record China GBM this approved forward look recurrent X,XXX would Our the newly joint Optune nearly patients that the to million in monotherapy largest prior adding as in versus The active up We global treated more

the other Optune within this opportunities, currently we begin to seeking for European to across the broaden diagnosed Lua drive testament quarter, we certification to expansion to this mission. colleagues want Wilco To for the proud our can obtain that will to our reiterate, I today, patients With than with in approval, XX financial on call physicians certify to performance Union. in to the over our am the all prescribe in are CE to and Moving With access treatment patients centers listening U.S., active of more I patient focus a do the of discuss turn the you colleagues. MPM In to call for there Lua cancer support thank how to Novocure over all EU. MPM I now at those that, our you forward country. results. are XXX Optune markets of

Wilco Groenhuysen

the strategic Novocure's Asaf. the well-positioned XXXX. second in and delivered commercial sustained priorities we financial momentum you, in to performance remain Thanks quarter, strong advance

of delivered versus the growth Our second second revenues XXXX. $XXX of GBM business net quarter quarter XX% representing million,

booked Our by year-over-year rates. and both the improvements continuous in revenues improvement increase XX% active U.S. The driven patients. revenue per patient active from to patients revenue XX% growth was in in per net by increase benefited reimbursement average

clean recognized the $XX our with fee million the administrative X, in progressing patients under September, and revenues can policy for ramp after beneficiaries second ensure on Medicare are for have policy from gained net we a This coverage good coverage we've understanding went XX% third was September coverage on Approximately of of how for XXXX. up we in currently effect Medicare active our quarter of if timely service quarter positive eligible Medicare processing Specifically, established built full claims. XXXX. therapy the they into started

we these We next processing the two additional continue appeal, to to will require quarters get if experience beneficiaries. and from expect over revenue experience an claims Medicare gain recognize sufficient

P&L. to a to Moving second reflecting continues and quarter down profit increasing Gross the scale. margin was ongoing $XX Gross gross in benefit million, efficiency initiatives margin. from XX%

invest advancement innovation to to the value our second invested We versus long-term the in XXXX. $XX This pre-clinical in Fields R&D and Tumor to outreach. due technology and creation and affairs strategy. X and Our extension programs, million science continue support X increase product in as in we increase trials, the our development capital quarter up expenses support was allocation research second in in an quarter, increase clinical XX% of investments continuing and unchanged, our of are Treating priorities for expenses personnel the development and medical to primarily our Phase and trial personnel of post-marketing Phase part

scientific increase Tumor our future across quarters, to continue expenses R&D acceptance we and programs Treating will development efforts advance Fields community. pre-clinical, of and the clinical increase to as product expect global We our in

expenses second in SG&A versus by quarter the efforts of up quarter and XXXX reimbursement second support $XX to launch expenses increased personnel were of related cost million, Optune increase of primarily business commercial XX% our driven in Our marketing the and Lua. role

profitability. consecutive Our our and quarter million, fourth $X.XX of income net was earnings representing per share, $X

as equivalents, evaluate earnings of based is adjusted be also depreciation, EBITDA, impact and non XXth, We We from We with quarter of ended growth share measurement in cash before on ended short in removes and and important based fund long-term interest this amortization taxes, June of We $XX metric earnings us compensation. both cash, quarter. management compensation same XXXX stability it GAAP the priorities. operating the an for attributable driven the capital believe hand provides and expenses. financial flexibility term million best XX material our performance $XX period rates $XXX fundamental in million financial our strength by million to coupled our investments, it strategic cash performance, XX% that financial improvement and business. the based million the believe disciplines specifically but XXXX. months three near-term with supplying reflects to structure, for our share and There's generated Adjusted EBITDA the increased from additional tax with on items and noncash value by prior our to by the

thank I operator Before I over for would Q&A, phone like interest call everyone to the continued to the Novocure. their for in on the hand

your most the in some strong the confident strategy, Fields we our the for Our Tumor commercial innovations long We and in clinical execution Treating our believe of to our team, that the record quarter remain extend morning. versus in results unlock business second potential momentum of time the for Thank and cancer. sustained are of highlighted increased intended prospects forms of another this future and platform fundamental of strong funded that aggressive drove term value. financial product investments track a the survival in performance you

the operator back turn for questions. to the will I over Now, call

Operator

first Our Greg with from of the Instructions] question comes SunTrust. Gilbert [Operator line

open. is line Your

Greg Gilbert

that that the is on discussed patients And which kind your see, the on dialogue is progress piece collaboration, fence it, in non for that willing not screen can you provide second that my development tangible with of material Thank of on the in them any cut we've Merck data has PDLX challenges any or part screens color the that see color lastly, in the of you to past pushed were types could you're good about other whether it’s approach, or question Bill, terms a limiting higher off starting starting? before? solved little be and background over science provide? to you in key that's And couple, you. you've a provide mean the terms that Have that study progressed good of time to more or how positivity, of intensity would of a would that point

Bill Doyle

Sure.

thanks always for started I So around want that we the good morning, interests. just state as dispersed are your we before completely world. to get

So but in little start let intensity. ask the answer, suggesting I with to be am when a I high an going directive, to people me

As clinical it being software. gets high all the patient, treat we of resolution know on remarks, when based MRIs on recall, research clear when have patients. And mentioned, that we the the preclinical based our the and we work array analyses date. all during I absolutely our prepared to of say I where And on exactly for a placed placement arrays are our

So, if brain in the and we tumors. configurations you the will their of of their the tissues know locations

lower seen published electrical the what patient-by-patient that very Tumor have after make a a on have intensity better we're So in basis survival maps tumors was proven to very a But, then that of was makes pain-staking able dose. a Journal tumors higher receive that, field Treating sense. specific a much Red what and what was Fields analysis what is was and overall

intensity that up commercial have we limit the solutions under we the arrays before? with engineering a the why mean haven't up. discs generate our over to developed teams intensity is are ceramic number a the a for the up our what scout first well Fields the which as on The intensity, now, turn that we decade number as turned are we this. ago and practically, does that, on system, of So, is reason we and the temperature working goes heat and There

just to and number what increase discs, was first that's The those described. the of we

the are a us spread short material We can science this rather nine. that relatively is to if discs in number of higher we clinic this path engineering of that intensity among elegance as more have if as the other So, example did And the solution, with this first enter period in But think well guests will will, an great a the fastest of that how us, and less comfort mentioned into out all XX the of of of clinic the system. allow a more solution script allows approaches deliver be to science we will in among than you was I fundamental to that, is this you believe intensity translate time. future. clinic a will in I the

combining is say probably presenting at the any was most and What therapy. trial. of obvious of we important science Treating science by would therapy question put design cancer. collaborated the with both Tumor the our in there, the of the design on benefits team therapy, started the second trial teams science Your to to potential they very Fields Merck work say PD-X can franchise that, to on here the Merck. teams and closely pre-clinical lung Treating forward, cancer Clearly as that this is lung by worked saw the I Merck with the potential We showing Tumor They've is this. Novocure that, to move and Merck wanted early power company's clinical is us levels they protocol. fact Fields highest I

this we're excited So, really trial off. kicked effort collaborative this was true a get and to

Greg Gilbert

squamous? points any patient non PD-LX positivity squamous or And cut color Thanks. the on makeup

Bill Doyle

this? if have any you to Ey, share want you detail on

Ely Benaim

going to They proportion is patients. lung metastatic advanced PD-LX call X% non-small higher. Sure. be keynoteXX question. Thank cover has you we cancer call score for to to have intrathoracic the The what the be a the cell and or population or tumor

Operator

Thank you.

the line question next Larry Fargo. comes from Biegelsen Our of with Wells

is Your line open.

Larry Biegelsen

front. both Bill, I'll for Thanks One Wilco and the them taking guys. up one morning ask for question. Good for

gross quarter. the see do there enrollment it off, it's Is gross questions if can on is do improvement the XX%. the Where able in analyses was it being per to picked strong you about QX XX%? Thanks talks by open Bill, and this Wilco or the to expect color quite you those any XXXX, for if or still And, that will that any those this clinical at going on revenue room of for P&L, math going? and on patient sites lastly, that in and the you trial net see our Bill analyses. you second Just in about on for Where new margin, talk up point colors taking can be half about, guys. interim the on yet whether in just trials at the first or cadence you

Wilco Groenhuysen

me as of questions Larry, all, it first Let here. great always, margin. morning off. Wilco Good Two gross kick

split now, something upside. reimbursement we we're potential what That's to distribution improvement I with in in as improving pickup, know, very anticipation. last committed in revenue ways which but we efficient That's mentioned do the is with to growth, prospective to in for go more that. our quarter. our well of the market is aspect as as our pleased some our XX% in do And the increase during XX% would the some little his that over goods XX, see one let's efficiency, extent to comparable become fulfillment unclear of we quarter say in process, a second polls continued the to our the second the lot of of there's you well. right that finding As we've see earlier quarters revenue I sold expect, operating order one as to With to with bit drivers and been with platform from the commitment leverage of say purchasing, improvement number course, to a improvement said up of further, cost gross think further a to

the there aspects we can and their of now more Medicare is more recognize revenue. of One that

for administrative where the enable particular be we've with a XX% claims mentioned developed also to expect come that we these the improvements, in full process plans see further the the for fruition. believe monthly but quarters, of will that now we we to significant talked that the You rate to successful in those that claims in improvements about should then us last few up that quarters at ramp Medicare another last we couple

Bill Doyle

pick of timing your thanks to with tail calling. I'll to So Ellie end and it question, of turn then over for completion. just respect trial the Larry, but up

So changed the trial opening, We further trial on share. quarter, thing have first we third if color any completion. haven't or of our quarter, estimates sort maybe, second terms of Ellie, in differentiate and quarter analysis you don't site that opening of to

Ely Benaim

Thank I already seen have you, know, We in a, trial we a early call would stabilization. that, you Bill. clinical signs. started say seeing environment we what

trails specific to trial will be So clinical and stable intense factors. trial reopening in transition this certain geographies, we successfully lounge regional high rate. that We believe clinical

strong and CROs with trial reopening authorities, with institution environment local a different geography. in clinical the very engaging continued We and

mentioned, take So, that pushing I'm I we are us of the what think we forward. teams have done. over and COVID And Asaf sort issues presented the of to proud have extremely like

the seeing our in opening through, and benefits sites. We new we're have and enrollment pushed

Operator

Thank you.

question the line next from of Kumar Vijay comes Our the with Evercore.

is open. line Your now

Vijay Kumar

should XX% on quarter. cancer details we there metric the lung trial your new X.X%. non-small on expecting? the cancer first curious what of line Congrats a here Maybe versus lung response similar the site rate an HEPANOVA non-small line therapy, and first analysis a the of from showing trials nice on baseline Asaf, be for objective as I'm given Is

Asaf Danziger

it's So, Vijay morning your and question. Thanks from to good for hear you. good

and cell Stage So, versus our collaboration for with cancer Merck expands Tumor Treating Fields cancer Stage X a non-small lung X second research treatment LUNAR of trial. line non-small and first line treatment our

trials of The really, to of in combination it I in -- to and think area. a in patients. you franchise with this our this really designed our work XX think development enroll So points if

to well-established soon. start overall is surrogate studies. Phase a in And We overall response rate and expect the endpoint in X PFS survival

in appropriate. not and yet the between we for to order each relationship look we one We think designed Sciences. statistics trial. at the with there's statistical indication, Merck not EF-XX. further no I This considerations will data trial. have this was disclosed by again, And was say So, ourselves and individual HEPANOVA each this the that, it's develop in designed in

Vijay Kumar

continues And main side; revenue beat, grow like U.S. seems, diverse and Understood. patients actual financial there patient the the clearly per up revenue per on plus then on and month, XX%. that that reimbursement stepped the to

curious you the now up active in the patients side, what's So any actual patient the are rates Thank foreseeable future? we seeing reimbursement strong covered? improve that. that compliance should as personally double-digit flights just looking reimbursement, or for on of U.S. me commercial I'm you. step rates be at driving On

Wilco Groenhuysen

Wilco, this or whole you start can maybe question. take

Wilco Groenhuysen

morning, reimbursement question. let's Wilco start the here, Good Vijay. with

I of was think the on We anticipation you in rates Medicare as noticed. driven and a revenue was improvement strong by that. commented example reimbursement largely our beat

You've for on the also as United preparation seen rate well pledge. as not areas the proof as business some on success increased cleaning well, in there collection, when a looked commercial instance, improvement necessarily success to some and higher but rates approval rates the you at successfully other the in We see the having States. in

show quarter, bit seen over quarters growth stronger the margins. top in you've and our developing factors last to, growth. to So the one is growth, on has that patient patient our how if as business. And of we'll line of little patient continue number impact stable with the With in it's the our respect course overall, it the the satisfied the second and of

shift we bit we've expect So to continue saw benefited that current shift but from is going become managed past year perhaps significant, diagnosed but GBM. incrementally. grow a once makes that to to do from nearly still completely to we the and it in from that prior not GBM less it’s little it's And

Operator

Thank you.

the comes Bednar from question next Jason Piper Our Sandler. line of with

Your is line open.

Jason Bednar

the you after path what the expand, commercial the everyone morning, here described questions that can for with see congrats Good too you completing two the to today? that in value you real the on want study, they're quarter Bill, ourselves maybe you as to the sit I but intensity phase don't paths of are far possible want and here. start you. ahead the I here, way taking a get nice on rate high

Bill Doyle

get an is Jason, this where trial, we're year to area don't on, focused XX. ahead. And first is one we number far really want So too this completing

focused the think And and in showed table we the optimistic personally into we get something from again, you the that are some very very that I also about deliberately We have can I'm pipeline. designs here. we of clinic pretty the design

a do with to our I lot has think safety inherent that profile.

we're prospects pathway so intensity give too a enthusiastic high here, to about use. we're you And commercial little into but early the the

Jason Bednar

men's just just and you can wondering then offer I'll understood inventory is of have how Zai Maybe maybe Novacure maybe we if how into product European other pending the of from a Okay the items, versus insight beyond idea should sales. at and helpful. international France century royalties that’s any couple being the then couple an Thanks. so to Lab, markets about years? over And think revenue of contribution plans move next

Bill Doyle

Okay.

Zai I'll but and Wilco China. So going there's to that make contribute, maybe lot in Pritesh Lab there I'm our to is partner a and first the comment ask

We the in a for know China I it's don't to you comments details. execution have that will terrifically expansion. report Wilco, organization partnership been in the than they're lift said talk Europe they about have on to more with might of have any expectations up our if all which and and responsible commercial But, be work. inventory helpful and professional to the Pritesh found you can That

Wilco Groenhuysen

Thank you, Bill.

the the that components are we course, to expect payments important the equipment start amortize One for of component in Zai approval component of sale Zai Let's China. the other overtime. those also some future, and is milestone and increase with with three the loyalties. There we could more of components in

the like stable but a royalties that So relatively elaborate equipment sale of for a I'd something seconds, is perhaps to if amount you like. that's on few

So first cost. essentially equipment is all, of of sale the at

be to impact So somewhat by zero a forward to feel question its going at very It good a in ago, on that the the sale little developing we a offset back because go of will It's XXX% managed about margin. where margin, margin some while own royalties GBM, margin. a our commercial asked while out gross business. equipment later of our date

if commercial success expect assigned but is costs. impact in may our great material But it benefits we of the coming will with course be short-run, in an material. think of have bit it launch from net it's don't on in So I a China. that, it the

Zai But a feel will that that good approval. the the So, we success have you about on inventory. and opportunity has obtaining minor impact

think course, over and exception will have years I with levels in the make successfully an be don't inventory acceptable to been we successful that. at Of to inventory, managing but sure can that, we Zai Zai and supply we've

Pritesh Shah

the pick you Great. I'll And Wilco. thank on And international question. up

before, for of CE as work expand we GBM can up path in had geographical and markets. as where making from are the geographies offers is the where continuing we're use our before, focusing we on shared opening in one other heard and and opportunity front. benefit mark It's have with for The with expansion right we're the me, now. of So on is, big now European and in in we beyond we're our European remarks, progress franchise this countries expansion, today that's the we essence also pending we another And you forward. that you that right levers growth one EU for X shared France, Asaf's

Jason Bednar

Thanks.

Pritesh Shah

and mentioning topic this up I by was wind will it. I Thanks. re-missed

market on been newly that, the of population, environment much China, So in international managing this in so for we've data. this patients busy strength recurrent happened approval received and our GBM quarter we in of terms largest Greater and the in diagnosed

add and time that, think as to international the knows everyone a I require again, decade Chinese coming who's therapies that into really can bridging of China So much a as almost students China availability. a study, always

this it's that to and team And onto achievements. kind page extraordinary really the for thank team Novocure achievements, the so, I of to want a our other with second it and falls testament Zai quarter a

Ashley Cordova

you do question? Operator, next queue the want to up

Operator

you. Thank

comes of Our with Yang line Difei question from next Mizuho. the

line open. Your is

Difei Yang

questions. and morning great the my quarter. Good thanks for Congratulations Hi. on taking

how Just should relative we forward there the may all, trial, about on trial questions, the And read think trial about how KEYTRUDA LUNAR. some than earlier out path think the first like we there? from a should KEYTRUDA of of couple to the And LUNAR?

Bill Doyle

Sure.

from good you. It's hear good to So morning.

think to the of XX. announcement number the launch the or there take a from things of I are So away

therapy. First applicability broad and of indication tumor fields the think foremost, I it's an of treating

which said, we've gene treat, all a solid cancers therapy on not specific not is into an of And we specific a to marker. on largest does is different deliver as market. cancers. deliver lung It as a fields, stage. So the we can is the what indication does depend essentially depend we this our We the going that can subset which all tumor believe can

So trial in non EF-XX of is in LUNAR, small cancer, four second first a is course stage line. cell lung

out well we very may but, build read earlier, expect it It right. that read to how across cancer indications. non franchise this lung cell small we out, will out is You're lines, global across

Difei Yang

early that Then the on curious share question launched now, Thank early early us. it as I'm data separate Okay. any you. you of link or there's if a program, was in clearance June. with could points

Bill Doyle

Pritesh, talk link and my going? you why about don't how it's

Pritesh Shah

question. for Thank Sure. that you

to the is that shared, a we usage. we have launched link help keep device track as of my So, patients

swap usage equipment can the do better have with either through tracking So to the we was to out patients of so the now usage usage. empowered before or the of device, my the to link, so the keep we are exchange of and device, track that tracked

my XX we that to with successfully. the all, early rollout also to able other the geographies. understand, into that pilot this are will on pathway and are look the And to an do pilot with initial results us in out continue confidence units U.S., forward So the launched in we U.S. first bring patients link and have of allowing about

Operator

Thank you.

question JPMorgan. next of the line comes Cory from Our with Kasimov

Your line is open.

Cory Kasimov

I just provide combo Corey. your on the be taking to helpful. question. either details or color trial hoping going for to This terms be anything could you Hey, of Thank if study, my you. additional terms Thanks. with just for the thank is some from Merck, you would was leading collaboration the Turner who's financial the for

Bill Doyle

Sure.

disclosed the of to closely them. the tend very we So, but with we a have say protocol worked the trial was not development We collaborative financial is activity. terms, that;

next We we share then the will and execute forward. steps and the the determine trial will data

clear work a to excited It's the best clearly oncology world, collaborating in cancer. the team. also in leader with they And We lung in non-small are team really perhaps cell the with them. that's are

as look Tumor we So, this tremendous Treating a Fields. for opportunity at

Cory Kasimov

any differences curious you posted negative just growth patterns quarter And what I'm in that's growth. there in physician, on between But geographies? Japan. underlying you're EMEA in it. driving Got scripts seeing script U.S. and different Are

Bill Doyle

quarter hospital, At ago, that the do XXXX. relatively had the do because of I Pritesh. seen a we Germany thing wrong numbers over this it's in we kind But in in I I'll into since one ebbs infrequent quarter and getting flows. U.S. one direction. the direction. you'll say to of same and hospital another a the -- time, another would have in the quarters and had disease in scripts now I've is, been one turn because positive flowed launched couple this of patients mean, question go vary a the But and those that GBM remember

I'll to of of do, in are think on there So can that phenotype. therapy. and the course, benefit We who particular therapy the than many scripts. the geographies, our a limited we're more on drive by currently we therapy. of are many, particular marker fact on focus focus to course, not genetic revenue or back patients all trying on for patients go a We

the limited by color and education, limited quarter. maybe are can Pritesh, on who patients the by we're a We in sometimes little doors. walk you But give the more

Pritesh Shah

Sure.

and Bill question. you thank So, for thank the you

our flow demand, And we will number experienced that we're start despite continue volume. QX the because focus what you ebbs this our that, here, proud commercial there. what and off active with that active patient are growth COVID typical revenue. experienced generating quarter, will Despite lead see of in the that that our of momentum see predicates sustained on subsequent we one I the of, impact we the what X,XXX and we patients patients on is and the that success and we focus on to in indicators So,

Operator

to now for closing remarks. Doyle concludes I'd today's like question-and-answer to Thank you. call This Bill session. back

Bill Doyle

I the same performance remarks. the organization on to have team unprecedented during pick up clearly Asaf are to unprecedented I mentioned their for of that Novocure us, These want They're and all scene times. you. for Thank the times. commend prepared these but during

improving very or our more that working home. are not future to have therapies is testament to therapy, that, their the on the serve Many they people additional That's absolute in development I our and preparing difficult. with It's their cancers are in are easy. serving effective and from it dedication always treat by near-term. of whether think to clinical ensuring organizations front in trial that our line and serve patients, patients research it's offices an so even patients our closed, our more them the

in personal And you. so, team. profound Also and just back my thank to work. express call thanks and have I their on for Thank we’ll interest to our Novocure everyone now appreciation for the get

Operator

Ladies this your participation. call. and you for conference gentlemen Thank today’s concludes

You may now disconnect.

NovoCure Limited (NVCR) 30 Jul 202020 Q2 Earnings call transcript